

Please type a plus sign (+) inside this box

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number  
Filing Date  
First Named Inventor Rose, Larry  
Group Art Unit 1645  
Examiner Name  
Attorney Docket Number 023070-087910US

RECEIVED  
MAR 15 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SM		5,468,611	A	Baxter-Lowe, et al.	11-21-1995	
SM		5,976,551	A	Mottez, et al.	11-02-1999	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SM		PCT	WO 95/11702	A1	Anergen Inc..	05-04-1995		
SM		PCT	WO 97/38310	A1	The Trustees of Columbia University in the City of New York	10-16-1997		

Examiner  
Signature

*Spluff*

Date  
Considered

8/19/02


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1321383 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Applicant Number	
Filing Date	
First Named Inventor	Rose, Larry
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	023070-087910US

RECEIVED  
MAR 15 2002  
TECH CENTER 1600/2900

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SSH		DeNardo, et al., "A Revolution in the Treatment of Non-Hodgkin's Lymphoma"; <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , Vol. 13, No. 4, pp. 213-223 (1998)	
SSH		DeNardo, "The Next Generation of Imaging and Therapeutic Agents for Lymphoma and Chronic Lymphocytic Leukemia"; <i>New Perspectives in Cancer Diagnosis and Management</i> , Vol. 3, No. 3, pp. 76-83 (1995)	
SSH	✓	Harris, et al., "MHC Class II Binding of Peptides Derived from HLA-DR 1"; <i>The Journal of Immunology</i> , Vol. 145, pp. 2169-2174 (1992)	
SSH		Rose, et al., "Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10"; <i>Cancer Immunol. Immunotherapy</i> Vol. 43 pp. 26-30 (1996)	
SSH		Abstract XP-002127145, Marianne K. Gjertsen, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer" <i>Vox Sanguinis</i> , Vol. 74 (suppl. 2): 489-495 (1998)	
SSH		Rose, et al. "Critical Lym-1 binding residues on polymorphic HLA-DR molecules"; <i>Molecular Immunology</i> Vol. 36 pp. 789-797 (1999)	

Examiner Signature

*Steff*

Date Considered

8/19/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1321383 v1